← Back to Screener
BioNexus Gene Lab Corp Common stock (BGLC)
Price$2.28
Favorite Metrics
Price vs S&P 500 (26W)-66.36%
Price vs S&P 500 (4W)-19.14%
Market Capitalization$5.32M
All Metrics
Book Value / Share (Quarterly)$3.79
P/TBV (Annual)2.39x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-10.71%
Cash Flow / Share (Quarterly)$-1.16
Price vs S&P 500 (YTD)-48.44%
Gross Margin (TTM)14.30%
Net Profit Margin (TTM)-23.33%
EPS (TTM)$-1.28
10-Day Avg Trading Volume0.00M
EPS Excl Extra (TTM)$-1.28
Revenue Growth (5Y)135.97%
EPS (Annual)$-0.90
ROI (Annual)-19.20%
Gross Margin (Annual)13.56%
Net Profit Margin (5Y Avg)-6.37%
Cash / Share (Quarterly)$0.64
Revenue Growth QoQ (YoY)-3.29%
ROA (Last FY)-15.32%
Revenue Growth TTM (YoY)-22.19%
EBITD / Share (TTM)$-1.28
ROE (5Y Avg)-5.00%
Operating Margin (TTM)-24.11%
Cash Flow / Share (Annual)$-1.37
P/B Ratio0.78x
P/B Ratio (Quarterly)1.44x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.82x
Net Interest Coverage (TTM)-41.45x
ROA (TTM)-18.27%
EV / EBITDA (TTM)37.87x
EPS Incl Extra (Annual)$-0.90
Current Ratio (Annual)3.81x
Quick Ratio (Quarterly)6.81x
3-Month Avg Trading Volume0.02M
52-Week Price Return-17.60%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.41
P/S Ratio (Annual)0.56x
Asset Turnover (Annual)0.91x
52-Week High$15.60
Operating Margin (5Y Avg)-5.43%
EPS Excl Extra (Annual)$-0.90
CapEx CAGR (5Y)86.72%
Tangible BV CAGR (5Y)134.18%
26-Week Price Return-57.61%
Quick Ratio (Annual)3.10x
13-Week Price Return-41.49%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.30x
Enterprise Value$4.165
Revenue / Share Growth (5Y)211.84%
Asset Turnover (TTM)0.56x
Book Value / Share Growth (5Y)97.77%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)6.51x
Pretax Margin (Annual)-16.77%
Cash / Share (Annual)$0.88
3-Month Return Std Dev81.96%
Gross Margin (5Y Avg)14.16%
Net Income / Employee (TTM)$-0
ROE (Last FY)-19.20%
Net Interest Coverage (Annual)-23.33x
EPS Basic Excl Extra (Annual)$-0.90
P/FCF (TTM)7.09x
Receivables Turnover (TTM)4.89x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.28
Receivables Turnover (Annual)8.74x
ROI (TTM)-22.15%
P/S Ratio (TTM)0.74x
Pretax Margin (5Y Avg)-5.47%
Revenue / Share (Annual)$5.34
Tangible BV / Share (Annual)$0.46
Price vs S&P 500 (52W)-52.69%
Year-to-Date Return-44.30%
5-Day Price Return-2.65%
EPS Normalized (Annual)$-0.90
ROA (5Y Avg)-4.78%
Net Profit Margin (Annual)-16.81%
Month-to-Date Return2.78%
Cash Flow / Share (TTM)$-0.03
EBITD / Share (Annual)$-0.89
Operating Margin (Annual)-16.55%
ROI (5Y Avg)-5.05%
EPS Basic Excl Extra (TTM)$-1.28
P/TBV (Quarterly)2.67x
P/B Ratio (Annual)0.60x
Inventory Turnover (TTM)6.73x
Pretax Margin (TTM)-24.35%
Book Value / Share (Annual)$4.63
Price vs S&P 500 (13W)-44.35%
Beta2.28x
P/FCF (Annual)10.85x
Revenue / Share (TTM)$4.01
ROE (TTM)-22.15%
52-Week Low$1.92
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
BGLCBioNexus Gene Lab Corp Common stock | — | -22.19% | -24.11% | -22.15% | $2.28 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $207.74 |
LHLabcorp Holdings Inc. | 25.31x | 7.25% | 9.92% | 10.28% | $269.19 |
DGXQuest Diagnostics Inc. | 21.75x | 11.78% | 14.10% | 13.88% | $196.31 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $91.07 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $57.85 |
VCYTVeracyte, Inc. | 39.66x | 16.01% | 11.17% | 5.33% | $33.45 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $51.20 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $21.29 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.44 |
About
BioNexus Gene Lab Corp supplies chemical raw materials to industrial, medical, automotive, and electronics manufacturers across Southeast Asia, while developing non-invasive liquid biopsy tests that analyze RNA to detect early disease biomarkers. The Company's blood-based tests are designed to reduce treatment costs and improve patient management through early disease identification.